Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Cleveland BioLabs, Inc. (NASDAQ: CBLI).

Full DD Report for CBLI

You must become a subscriber to view this report.


Recent News from (NASDAQ: CBLI)

Cleveland Biolabs Reports First Quarter 2018 Financial Results and Development Progress
BUFFALO, NY / ACCESSWIRE / May 15, 2018 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the first quarter ended March 31, 2018. Cleveland BioLabs reported a net loss of $(1.2) million, excluding minority interests, for the first quart...
Source: ACCESSWIRE
Date: May, 15 2018 08:00
Cleveland Biolabs Announces Progress on European Marketing Authorization Application
BUFFALO, NY / ACCESSWIRE / March 28, 2018 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported that the company has received Day 120 review questions from the European Medicines Agency (EMA) regarding the company's Marketing Authorization Application (MAA) for entolimod. The MAA seeks app...
Source: ACCESSWIRE
Date: March, 28 2018 17:05
Cleveland Biolabs Reports 2017 Financial Results and Development Progress
BUFFALO, NY / ACCESSWIRE / March 6, 2018 / Cleveland BioLabs, Inc. (NASDAQ: CBLI) today reported financial results and development progress for the fourth quarter and year ended December 31, 2017. Cleveland BioLabs reported a net loss, excluding minority interests, of $(1.2) million for th...
Source: ACCESSWIRE
Date: March, 06 2018 08:00
Pluristem - Hidden Treasures And Sudden Catalysts
Investment Thesis: Pluristem ( PSTI ) is among the cell therapy companies which are racing to completion of a Phase III trial and initiation of two others in the coming months which look to address unmet needs in the medical community. Pluristem primarily utilizes two different placenta-d...
Source: SeekingAlpha
Date: February, 08 2018 08:18
Cleveland Biolabs' Delay Supports Competitor Advantage In Acute Radiation Syndrome
Investment Thesis: Cleveland Biolabs ( CBLI ) is a microcap stock who has seen its share price collapse over the past 5 years due to concerns over their lead product Entomolid, primarily marketed as a radiation countermeasure. They have recently seen an uptick in their share price as they...
Source: SeekingAlpha
Date: January, 10 2018 18:14
Wired News - FDA Cleared IND Application of Capricor to Conduct Phase-2 Trial of CAP-1002 for Duchenne Muscular Dystrophy
Stock Monitor: Cleveland BioLabs Post Earnings Reporting LONDON, UK / ACCESSWIRE / December 01, 2017 / Active-Investors issued a free report on Capricor Therapeutics, Inc. (NASDAQ: CAPR ), which is readily accessible upon registration at www.active-investors.com/registration-sg/?symb...
Source: ACCESSWIRE IA
Date: December, 01 2017 07:00
Cleveland BioLabs Reports Third Quarter 2017 Financial Results and Development Progress
BUFFALO, NY--(Marketwired - Nov 14, 2017) -  Cleveland BioLabs, Inc. ( NASDAQ : CBLI ) today reported financial results and development progress for the third quarter ended September 30, 2017. Cleveland BioLabs reported a net loss of $(1.3) million, excluding minority interests, fo...
Source: Marketwired
Date: November, 14 2017 08:20
Cleveland BioLabs Reports Second Quarter 2017 Financial Results and Development Progress
BUFFALO, NY--(Marketwired - Aug 14, 2017) - Cleveland BioLabs, Inc. ( NASDAQ : CBLI ) today reported financial results and development progress for the second quarter ended June 30, 2017. Cleveland BioLabs reported a net loss of $(5.6) million, excluding minority interests, for the sec...
Source: Marketwired
Date: August, 14 2017 08:12
Cleveland Biolabs Countermeasure for Acute Radiation Syndrome, Pipeline Review, and Market Potential
NEW YORK, NY / ACCESSWIRE / August 11, 2017 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report with no obligation on Cleveland BioLabs, Inc. (NASDAQ: CBLI), a biopharmaceutical c...
Source: ACCESSWIRE IA
Date: August, 11 2017 08:03
Cleveland BioLabs up 6% on rumored entolimod DoD contract
Thinly traded nano cap Cleveland BioLabs ( CBLI +6.2% ) perks up on more than triple normal volume, albeit on turnover of only 187K shares, on rumors about a new contract with the U.S. Department of Defense (DoD) related to radiation countermeasure entolimod . More news on: Cleveland Bi...
Source: SeekingAlpha
Date: August, 09 2017 10:19

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-08-162.0031.982.051.8714,703
2018-08-152.152.012.621.921237,933
2018-08-142.002.052.1392.0028,835
2018-08-132.25421.96572.25421.854225,810
2018-08-102.332.332.382.267,388

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-08-161,0835,49719.7017Cover
2018-08-1528,20575,56137.3275Short
2018-08-142,00012,58915.8869Cover
2018-08-132,10525,9638.1077Cover
2018-08-10308083.7129Cover

* Cover Mode

Short Analysis provided by Squeeze Report. Get a complete short report on CBLI.


About Cleveland BioLabs, Inc. (NASDAQ: CBLI)

Logo for Cleveland BioLabs, Inc. (NASDAQ: CBLI)

Not available

 

Contact Information

 

 

Current Management

  • Yakov Kogan / CEO
  • Rachael Llevine / IR

Current Share Structure

  • Market Cap: $31,696,334 - 05/14/2018
  • Issue and Outstanding: 11,279,834 - 05/05/2017

 


Recent Filings from (NASDAQ: CBLI)

Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 15 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: May, 15 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 01 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 28 2018
Prospectus filed under Rule 424(b)(3)
Filing Type: 424B3Filing Source: edgar
Filing Date: March, 21 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: March, 12 2018
Additional proxy soliciting materials - definitive
Filing Type: DEFA14AFiling Source: edgar
Filing Date: March, 12 2018
Annual report with a comprehensive overview of the company
Filing Type: 10-KFiling Source: edgar
Filing Date: March, 06 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: March, 06 2018
Amendment to the SC 13G filing
Filing Type: SC 13G/AFiling Source: edgar
Filing Date: February, 28 2018

 

 


Daily Technical Chart for (NASDAQ: CBLI)

Daily Technical Chart for (NASDAQ: CBLI)


Stay tuned for daily updates and more on (NASDAQ: CBLI)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: CBLI)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in CBLI is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. DD Report does not own any shares of CBLI and does not buy, sell, or trade any shares of CBLI. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: http://dd.report/disclaimer/